Tronox Holdings plcTROX is working through a titanium dioxide (TiO2) downcycle with early signs that volumes and commercial ...

Tronox Holdings plcTROX entered 2026 with a split narrative. Volume trends improved into late 2025 and pricing actions began ...

Researchers directly observed bulk oxygen spillover in catalysts for the first time, revealing that a catalyst's interior can ...

Sulfate radical (SO4•- )-based advanced oxidation processes (AOPs) are appealing for removing persistent organic pollutants ...

Study reveals defects in graphene enable covalent bonding with TiO2, creating hybrid states that boost charge transfer and ...

TiO2 photocatalysts have great potential for environmentally friendly applications, such as pollution remediation, artificial photosynthesis and CO2 ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. After the ...

Running 17 best walking shoe deals from Hoka, Asics, and Nike — spring deals with up to 47% off Running I just found the 9 best Asics deals on Amazon — and runners will not be disappointed Running ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...